journal article·2018-10-03Open access

NanoMIL-100(Fe) containing docetaxel for breast cancer therapy

Mahsa Rezaei, Alireza Abbasi, Reyhaneh Varshochian, Rassoul Dinarvand, Mahmood Jeddi-Tehrani

Abstract

Metal-organic frameworks, such as MIL-100, have been recently introduced as promising drug carriers due to their notable characteristics such as stability, biocompatibility and owning large porosity which may admit a broad range of drugs with different molecular sizes. In this study, we firstly proposed an accessible top-down approach using ultrasound method to prepare nanoMIL-100 and secondly, evaluated its potentials as an anticancer nanocarrier. This is the first report that docetaxel (DTX) as a highly hydrophobic anticancer drug was encapsulated in nanoMIL-100 with the drug payload of 57.2 wt%. Characterizations of the prepared nanoMIL-100 and DTX-loaded nanoMIL-100 were performed by PXRD, FT-IR, N2 adsorption, DLS and FE-SEM. Moreover, the drug loading and release processes were quantified by HPLC. The in vitro release of DTX from the prepared nanocarrier was investigated in two pH values, 7.4 and 5.5. The toxic effect of DTX-loaded nanoMIL-100 was examined on human breast cancer cell line, MCF-7, and a significant decrease was observed in IC50 value (0.198 μg/mL) at the first 24 h in comparison with the free drug (4.9908 μg/mL). This nanocarrier may, thus offer promising potentials as a novel cytotoxic drug delivery system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoparticle-Based Drug Delivery · X-ray Diffraction in Crystallography

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

,

Funding

University of Tehran · Tehran University of Medical Sciences

References (61)

Show source-provided references
1. 10.1016/j.biomaterials.2004.10.01210.1016/j.biomaterials.2004.10.012 ↗
2. 10.3109/21691401.2015.102962510.3109/21691401.2015.1029625 ↗
3. 10.1002/smll.20120170210.1002/smll.201201702 ↗
4. 10.1166/jbn.2017.235610.1166/jbn.2017.2356 ↗
5. 10.3109/21691401.2015.112962510.3109/21691401.2015.1129625 ↗
6. Dhankhar R, Vyas S, Jain A, et al. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Nanomed Biotechnol. 2010;38:230–249.
7. 10.1021/acs.chemrev.5b0012510.1021/acs.chemrev.5b00125 ↗
8. 10.1038/4624810.1038/46248 ↗
9. 10.1016/j.ccr.2009.05.01910.1016/j.ccr.2009.05.019 ↗
10. 10.1166/jnn.2016.1097410.1166/jnn.2016.10974 ↗
11. 10.1002/anie.20080606310.1002/anie.200806063 ↗
12. 10.1016/j.cclet.2016.01.02110.1016/j.cclet.2016.01.021 ↗
13. 10.1021/acsami.5b1254110.1021/acsami.5b12541 ↗
14. 10.1038/nmat260810.1038/nmat2608 ↗
15. Horcajada P, Serre C, Vallet-Regí M, et al. Metal-organic frameworks as efficient materials for drug delivery. Angew Chem Int Ed Engl. 2006;45:5974–5978.10.1002/anie.200601878 ↗
16. 10.2217/nnm.11.6910.2217/nnm.11.69 ↗
17. 10.1021/ja710973k10.1021/ja710973k ↗
18. 10.1517/17425247.2013.74158310.1517/17425247.2013.741583 ↗
19. 10.1021/la501255510.1021/la5012555 ↗
20. 10.1039/C4TB00725E10.1039/C4TB00725E ↗
21. 10.1002/adhm.20120045410.1002/adhm.201200454 ↗
22. 10.1016/j.micromeso.2015.08.01710.1016/j.micromeso.2015.08.017 ↗
23. 10.1039/C5NJ02741A10.1039/C5NJ02741A ↗
24. 10.3109/1061186X.2015.107329410.3109/1061186X.2015.1073294 ↗
25. 10.1166/jbn.2016.228210.1166/jbn.2016.2282 ↗
26. 10.3109/21691401.2013.84556910.3109/21691401.2013.845569 ↗
27. 10.1038/srep3695710.1038/srep36957 ↗
28. Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol. 2006;8:S48–S55.
29. 10.1186/1556-276X-6-26010.1186/1556-276X-6-260 ↗
30. Yin H, Liao L, Fang J. Enhanced permeability and retention (EPR) effect based tumor targeting: the concept, application and prospect. JSM Clin Oncol Res. 2014;2:1010.
31. 10.1038/am.2015.8310.1038/am.2015.83 ↗
32. 10.1080/21691401.2017.133702910.1080/21691401.2017.1337029 ↗
33. Ito T, Hagiwara A, Takagi T, et al. Local administration of methotrexate bound to activated carbon particles (MTX-CH) for treating cancers in mice. Anticancer Res. 2002;23:1401–1404.
34. 10.1021/acsami.6b0279010.1021/acsami.6b02790 ↗
35. 10.7150/thno.1968010.7150/thno.19680 ↗
36. 10.1166/jbn.2016.223410.1166/jbn.2016.2234 ↗
37. 10.1039/B704325B10.1039/B704325B ↗
38. 10.1002/smll.20110044210.1002/smll.201100442 ↗
39. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
40. 10.1021/cm101778g10.1021/cm101778g ↗
41. Zhao Y, Zhang J, Han B, et al. metal-organic framework nanospheres with well-ordered mesopores synthesized in an ionic liquid/CO2/surfactant system. Angew Chem Int Ed. 2011;50:636–639.10.1002/anie.201005314 ↗
42. 10.1038/nchem.102610.1038/nchem.1026 ↗
43. 10.1016/j.ccr.2014.10.00810.1016/j.ccr.2014.10.008 ↗
44. 10.1016/j.ccr.2015.02.01410.1016/j.ccr.2015.02.014 ↗
45. 10.1039/c2jm15675j10.1039/c2jm15675j ↗
46. 10.1111/cbdd.1228810.1111/cbdd.12288 ↗
47. 10.1016/j.jcis.2003.12.00310.1016/j.jcis.2003.12.003 ↗
48. 10.1039/c3dt52698d10.1039/c3dt52698d ↗
49. 10.1038/nchem.156910.1038/nchem.1569 ↗
50. 10.1016/j.ccr.2015.08.00810.1016/j.ccr.2015.08.008 ↗
51. 10.3891/acta.chem.scand.44-065310.3891/acta.chem.scand.44-0653 ↗
52. 10.1016/j.biomaterials.2015.02.10810.1016/j.biomaterials.2015.02.108 ↗
53. 10.1039/c3tb20653j10.1039/c3tb20653j ↗
54. 10.1016/j.ajps.2013.08.00110.1016/j.ajps.2013.08.001 ↗
55. 10.1186/s11671-016-1798-610.1186/s11671-016-1798-6 ↗
56. Arora S, Saharan R, Kaur H, et al. Attachment of docetaxel to multiwalled carbon nanotubes for drug delivery applications. Adv Sci Lett. 2012;5:1–6.
57. 10.2147/IJN.S8958410.2147/IJN.S89584 ↗
58. 10.1039/C6RA27054A10.1039/C6RA27054A ↗
59. 10.1039/C3CC47666A10.1039/C3CC47666A ↗
60. Ruyra A, Yazdi A, Epsin J, et al. Synthesis, culture medium stability, and in vitro and in vivo Zebrafish embryo toxicity of metal-organic framework nanoparticles. Chem Eur J. 2014;20:1–12.
61. 10.1021/cr400295a10.1021/cr400295a ↗